Abbott Laboratories reports Q2 results today having lost ground sharply since the prior earnings preview, with the stock sliding 6.2% over the past week to $89.27 — a notably weaker entry point than the $93.93 level flagged in the July 12 article.
The sell-off has not triggered defensive repositioning in options. The put/call ratio of 0.71 remains barely above its 20-day average of 0.695 — less than one standard deviation — meaning options traders have not rushed for downside protection despite the price drop. Short interest has ticked up 6.3% over the past week to 1.3% of the free float, a small reversal of the month-long retreat described previously, but still far too modest to read as a bearish conviction trade. Borrow availability remains essentially unlimited, and the cost to borrow, while up 60% week-on-week in percentage terms, has merely risen from 0.31% to 0.49% — negligible in absolute terms. Positioning looks calm rather than cautious, with no meaningful squeeze pressure and options traders showing little urgency.
The analyst picture is consistent with the prior article but has softened incrementally at the margin. Evercore ISI's Vijay Kumar trimmed his target a second time on July 6 — from $120 to $112 — while holding Outperform. The broader Street remains constructive, with 16 buy ratings and a mean target near $116, implying roughly 30% upside from current levels. Bulls point to Abbott's diversified platform across diabetes, structural heart, and diagnostics as a catalyst for accelerating growth into 2027, and note the stock trades at roughly 14.5x forward consensus EPS — a discount to medtech peers. Bears focus on international revenue exposure and ongoing softness in the nutritional segment, which constrains the path to a volume-driven re-rating. One notable data point: Abbott's CFO Philip Boudreau bought 2,200 shares in late April at $91.50, and independent director Daniel Starks added 10,000 shares at $92.65 around the same time — both purchases now sitting modestly underwater, adding a layer of interest to whether today's print validates that conviction.
The Q2 release is therefore a test of whether Abbott's diagnostics and device segments can deliver the kind of outperformance needed to rebuild confidence in the full-year guide — and whether management's optimism, underscored by insider buying near current levels, is vindicated by the numbers.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
